基本信息
浏览量:6
职业迁徙
个人简介
My research focus on four streams of work, vaccine policy research, the development of novel methodological tools, integration of serological data into models to understand transmission and real-time modelling and outbreak response. I have also 10 years of experience working in a public health institution (Public Health England).
Real-time modelling and outbreak response I have a keen interest in the particular problem of real-time modelling for outbreak response. This includes understanding the sources of uncertainties and including these in the inference methods, and designing fast and efficient models to inform policy makers. As part of the modelling team for PHE (then HPA), I built in real-time the model that informed the UK Scientific Advisory Group for Emergencies and the JCVI on vaccination strategy during the 2009 pandemic in the UK and was part of the modelling taskforce at the London School of Hygiene and Tropical Medicine during the 2014 Ebola crisis in West Africa. I am now fully committed to provide modelling support for the COVID-19 outbreak response.
Vaccine policy research I developed transmission models and cost-effectiveness analyses to support policy makers in decisions regarding changes to immunization programmes. For the last 10 years, I have been a regular contributor to the Joint Committee on Vaccination and Immunisation in the UK. In particular I have developed models and undertaken the cost-effectiveness analyses supporting the vaccination of pregnant women against seasonal influenza, the introduction of paediatric influenza vaccination in children, quadrivalent influenza vaccines and assessing the impact of the new paediatric arm of the flu immunisation programme on the pre-existing elderly arm. I have also lead studies on the cost-effectiveness of influenza and high dose influenza vaccines.
Development of novel methodological tools I am driven to improve existing methodological tools whenever possible in particular to fully exploit new data streams. In the past years I have developed with various academic collaborators novel methods to improve the inference of transmission model parameters using surveillance data. With collaborators at the London School of Economics I have developed a method to include a diffusion process to represent time varying quantities when mechanisms of change are difficult to assess, co-developed two R packages, one for handling jointly genetic and epidemiological information, and the second for performing evidence synthesis and cost-effectiveness from influenza surveillance data.
Integration of serological data into models to understand transmission As a result of my interactions with epidemiologists and virologists, I have developed a strong interest in using biological markers (in particular antibody titres from sera) to better understand pathogens transmission. I have developed a framework to derive infection incidence from sequential serology while integrating potential additional data sources, a new type of model including the dynamics of titre changes alongside the dynamics of transmission. During the 2014 Ebola crisis in West Africa, I have developed a household serological survey in the Democratic Republic of Congo to assess asymptomatic transmission. The resulting data were analysed using a Bayesian mixture model. The protocol was then adapted to survey returning healthcare workers, estimate potential asymptomatic infection rate and link it with risk while in the field.
Real-time modelling and outbreak response I have a keen interest in the particular problem of real-time modelling for outbreak response. This includes understanding the sources of uncertainties and including these in the inference methods, and designing fast and efficient models to inform policy makers. As part of the modelling team for PHE (then HPA), I built in real-time the model that informed the UK Scientific Advisory Group for Emergencies and the JCVI on vaccination strategy during the 2009 pandemic in the UK and was part of the modelling taskforce at the London School of Hygiene and Tropical Medicine during the 2014 Ebola crisis in West Africa. I am now fully committed to provide modelling support for the COVID-19 outbreak response.
Vaccine policy research I developed transmission models and cost-effectiveness analyses to support policy makers in decisions regarding changes to immunization programmes. For the last 10 years, I have been a regular contributor to the Joint Committee on Vaccination and Immunisation in the UK. In particular I have developed models and undertaken the cost-effectiveness analyses supporting the vaccination of pregnant women against seasonal influenza, the introduction of paediatric influenza vaccination in children, quadrivalent influenza vaccines and assessing the impact of the new paediatric arm of the flu immunisation programme on the pre-existing elderly arm. I have also lead studies on the cost-effectiveness of influenza and high dose influenza vaccines.
Development of novel methodological tools I am driven to improve existing methodological tools whenever possible in particular to fully exploit new data streams. In the past years I have developed with various academic collaborators novel methods to improve the inference of transmission model parameters using surveillance data. With collaborators at the London School of Economics I have developed a method to include a diffusion process to represent time varying quantities when mechanisms of change are difficult to assess, co-developed two R packages, one for handling jointly genetic and epidemiological information, and the second for performing evidence synthesis and cost-effectiveness from influenza surveillance data.
Integration of serological data into models to understand transmission As a result of my interactions with epidemiologists and virologists, I have developed a strong interest in using biological markers (in particular antibody titres from sera) to better understand pathogens transmission. I have developed a framework to derive infection incidence from sequential serology while integrating potential additional data sources, a new type of model including the dynamics of titre changes alongside the dynamics of transmission. During the 2014 Ebola crisis in West Africa, I have developed a household serological survey in the Democratic Republic of Congo to assess asymptomatic transmission. The resulting data were analysed using a Bayesian mixture model. The protocol was then adapted to survey returning healthcare workers, estimate potential asymptomatic infection rate and link it with risk while in the field.
研究兴趣
论文共 140 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Pablo Noel Perez-Guzman,Stephen Longa Chanda,Albertus Schaap,Kwame Shanaube,Marc Baguelin, Sarah Nyangu, Muzala Kapina Kanyanga,Patrick Walker,Helen Ayles,Roma Chilengi,Robert Verity,Katharina Hauck,
crossref(2024)
Marta C. Nunes,Edward Thommes,Holger Fröhlich,Antoine Flahault,Julien Arino,Marc Baguelin,Matthew Biggerstaff, Gaston Bizel-Bizellot,Rebecca Borchering, Giacomo Cacciapaglia,Simon Cauchemez, Alex Barbier--Chebbah,
Infectious Disease Modellingno. 2 (2024): 501-518
The Lancet. Public healthno. 3 (2023): e174-e183
NATURE COMMUNICATIONSno. 1 (2023)
Harrison Manley, Thomas Bayley, Gabriel Danelian, Lucy Burton,Thomas Finnie,Andre Charlett, Nick Watkins,Paul Birrell,Daniela De Angelis,Matt J Keeling,Sebastian J Funk,Graham Medley,
medRxiv (Cold Spring Harbor Laboratory) (2023)
Katy A M Gaythorpe, Rich G Fitzjohn,Wes Hinsley,Natsuko Imai,Edward S Knock, Pablo N Perez Guzman,Bimandra Djaafara,Keith Fraser,Marc Baguelin,Neil M Ferguson
Katharine Sherratt, Anna C. Carnegie,Adam Kucharski,Anne Cori,Carl A. B. Pearson, Christopher I. Jarvis,Christopher Overton,Dale Weston,Edward M. Hill,Edward Knock,Elizabeth Fearon,Emily Nightingale,
bioRxiv (Cold Spring Harbor Laboratory) (2023)
引用0浏览0引用
0
0
Nature communicationsno. 1 (2023): 4279-9
SSRN Electronic Journalno. 1 (2023): 1-12
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn